arrow
S

Steven I. Sherman

the university of texas m d anderson cancer center
H指数:90
被引数:5.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases

RET驱动的骨保护素表达将甲状腺髓样癌与成骨性骨转移联系起来

2026-08-270
OA
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-RefractoryDifferentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study
THYROID
IF6.7
2024-03-015
OAAI
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial

卡博替尼治疗先前治疗的放射性碘难治性分化型甲状腺癌: COSMIC-311 3期试验的更新结果

CANCER
IF5.1
2022-10-1936
OAAI
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
2020-01-0153
OAAI